LeMaitre Vascular vs STAAR Surgical
LeMaitre Vascular reported revenue of $250 million in fiscal 2025, about the same as STAAR Surgical's $239 million in fiscal 2025. LeMaitre Vascular's revenue grew 13.5% in its latest year, and STAAR Surgical's fell 23.7%. LeMaitre Vascular had an operating margin of 27.2%, against -38.3% at STAAR Surgical. Free cash flow was $74 million at LeMaitre Vascular and −$40 million at STAAR Surgical. Their fiscal years end in different months (December 31 and January 2), so the periods don't line up exactly.
Side by side
| LeMaitre Vascular | STAAR Surgical | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Jan 2, 2026 |
| Revenue | $250M | $239M |
| Revenue growth | 13.5% | −23.7% |
| Revenue growth a year, last 5 years | 14.0% | 7.9% |
| Gross margin | 71.5% | 76.2% |
| Operating margin | 27.2% | −38.3% |
| Net margin | 23.1% | −33.6% |
| Free cash flow | $74M | −$40M |
| Free cash flow margin | 29.8% | −16.7% |
| Return on capital | 25.5% | — |
| Net debt to EBITDA | −2.4x | — |
| Dividends and buybacks | $20M | $6M |
| Change in diluted share count | 0.7% | 0.9% |
| Last close | $80.89 | $25.21 |
| P/E at the last close | 29.4× | — |
| Insider trades, last 12 months | sold $30.0 million | bought $62.8 million, sold $0 |
| Piotroski F-score | 5 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
LeMaitre VascularSTAAR Surgical
Operating margin
Percent of revenue
LeMaitre VascularSTAAR Surgical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LeMaitre VascularSTAAR Surgical
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the LeMaitre Vascular and STAAR Surgical pages.